Doximity Q1 revenue $145.9M (+15%), adj. EBITDA $79.8M (+21%), raises FY guidance

Doximity, Inc.

2026-Q1 EPS reported $0.27 vs consensus $0.29 ▼ miss (-6.5%)

Revenue $145.9M (+15% YoY); net income $53.3M (36.5% margin); non-GAAP EPS $0.36.
Adjusted EBITDA $79.8M (+21% YoY), margin 54.7%; operating cash flow $62.1M (+51%).
FY2026 guidance raised: revenue $628M-$636M, adj. EBITDA $341M-$349M.
AI suite fastest growing, up 5x YoY; over 630K prescribers used workflow tools.
Acquired Pathway Medical (details in separate release).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.